The 2022/23 influenza season could see Seqirus produce 55 million vaccines for the US alone, but fluctuating demand across hemispheres means the firm must manage scalability in a variety of ways. Seqirus has long had a leading role in the seasonal influenza space through its portfolio of products, including both egg-based and cell-based vaccine. And last month, the firm began shipping its portfolio across the US and claimed it is prepared to supply more than 55 million doses, if required. To…